title: Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis.
abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) of unknown origin characterized by epithelial cell dysfunctions, accumulation of fibroblasts and myofibroblasts and relentless deposition of extracellular matrix (ECM). Improved diagnostic accuracy and better trial design have provided important insights from recent clinical trials. Perhaps the most important insight was the realization that 'standard therapy' was actually harmful! This review summarizes the current understanding of the cell types that are altered in IPF and the pathogenic mechanisms that have been identified. It also reviews recent clinical trial results and interpretations. Finally, we highlight attractive biologic targets and therapies in development with recommendations for future therapeutic avenues.
authors.affiliation: Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
authors.forename: Hillary
authors.initials: H
authors.lastname: Loomis-King
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Flaherty
authors.forename: Bethany B
authors.initials: BB
authors.lastname: Moore
mesh_terms: D000818:Animals; D015897:Comorbidity; D065627:Familial Primary Pulmonary Hypertension; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000453:epidemiology; D054990:Idiopathic Pulmonary Fibrosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy